Comments
Religare
Aarti Ind (Buy)
CMP: ₹423.30
Target: ₹555
Backed by 14 per cent overall volume growth and 9-10 per cent growth in specialty chemicals, Aarti Industries’ Q1 operating profit margins grew about 17 per cent y-o-y, largely in line with the guided about 20 per cent y-o-y growth target. While specialty chemicals EBIT grew by 21 per cent y-o-y to ₹118 crore, pharmaceutical EBIT declined by 11 per cent y-o-y on account of maintenance shutdown at one of the caffeine production units. Revenue traction, however, is expected to improve going forward on a) the caffeine unit resuming operations; and b) USFDA approval for four products which will contribute to sales Q2FY16 onwards.
Aarti Industries is investing about ₹500 crore over FY15-FY17, which will lead to a) expansion in NCB capacity from 66-75 TMT in Q2-Q3FY16; b) PDA expansion to 1000TPA from 250 TPQ in a phased manner over FY16; and c) toluene capacity of 30 TMT by FY16-end. Expanded capacities would shore up ARTO’s volume/EBITDA by 15-20 per cent /20-24 per cent y-o-y over FY16E-FY18E.
Aarti Industries has received HC approval for amalgamation of its subsidiaries with itself, leading to a reduction of 5.95 per cent in equity capital and thus improving EPS and ROE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.